Listen on the go
Downloads

View and download resources from this activity to support your learning or share with colleagues.

Download Slides
Transcript
Download Slides
Transcript
Download Slides
Transcript
CORRECT!
Next question
Faculty & Disclosures
Dr Stephen Liu

Georgetown University Medical Center, Washington, DC, USA

Stephen Liu, MD, is an Associate Professor of Medicine and the Director of Thoracic Oncology at Georgetown University.

Dr Liu is the current Head of the Phase I, Developmental Therapeutics program at the Lombardi Comprehensive Cancer Center and his focus is on the treatment of lung cancer and novel drug development.

His research has been published in journals such as the New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology and Cancer Discovery. In addition to leading national and global clinical trials for the treatment of lung cancer, Dr Liu has also served as the chief editor for Frontiers in Thoracic Oncology since 2014.

Dr Stephen Liu discloses: Advisory board/consultant roles for AstraZeneca, BeiGene, Blueprint Medicines, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly and Co., G1 Therapeutics, Inc., Genentech/Roche, Guardant Health, Inivata Limited, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Merck/Merck Sharp & Dohme Corp., PharmaMar S.A., Pfizer Inc., Regeneron Pharmaceuticals and Takeda; Research grants to his institution from Alkermes, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Corvus Pharmaceuticals, Eli Lilly and Co., Genentech, Lycera Corp., Merck, Merus, Pfizer Inc., Rain Therapeutics Inc., RAPT Therapeutics, Spectrum Therapeutics and Turning Point Therapeutics, Inc.
touchONCOLOGY touchONCOLOGY

Non-small cell lung cancer

Watch interviews and expert perspectives covering the latest findings for the management of non-small cell lung cancer.

Curriculum Activities

Lung Cancer
Watch Time: 27 mins
touchTALKS
A moving target: Assessing the role of EGFR-TKIs in early-stage NSCLC
Dr Stephen Liu Translations available:

Dr Stephen Liu presents the latest data and future directions of targeted therapy within the rapidly evolving treatment landscape for patients with early-stage NSCLC.

Learning objectives
Learning Objectives
  • Recall the latest efficacy and safety data for EGFR-TKIs for patients with early-stage EGFR-mutant NSCLC
  • Describe how the evolving use of EGFR-TKIs may impact the current recommendations for mutation testing in NSCLC
  • Discuss how EGFR-TKIs may be incorporated into the evolving treatment pathway for early-stage NSCLC, now and in the future
Lung Cancer
Watch Time: 36 mins
touchEXPERT OPINIONS
Progress in EGFR-mutant NSCLC: Where are we going?
Dr Raffaele Califano, Dr Lecia Sequist, Prof. Yi-Long Wu Translations available:

Watch leading non-small cell lung cancer (NSCLC) experts discuss the current standard and the latest advancements in epithelial growth factor receptor (EGFR)-targeted therapy.

Learning objectives
Learning Objectives
  • Describe the rationale for and clinical trial data associated with combination therapy in first-line EGFR-mutant NSCLC
  • Describe the mechanisms of resistance to third-generation EGFR-TKIs and strategies to manage drug resistance in the second-line setting
  • Recall data on emerging therapeutic strategies for early-stage EGFR-mutant NSCLC and how this may impact the metastatic treatment landscape
Lung Cancer
Watch Time: 40 mins
touchPANEL DISCUSSION
The role of MDTs in optimizing NSCLC management: From early disease and beyond
Prof. Solange Peters (Chair), Prof. Walter Weder, Prof. Françoise Mornex, Prof. Albrecht Stenzinger Translations available:

This activity brings together a panel of experts involved in the management of patients with non-small cell lung cancer (NSCLC) to discuss how optimal multidisciplinary team practices and communication can translate to improved patient care.

Learning objectives
Learning Objectives
  • Appraise optimal working practices for a successful multidisciplinary team (MDT) approach to the management of patients with non-small cell lung cancer (NSCLC)
  • Describe communication strategies for MDT members when assessing patient needs and making treatment decisions in patients with NSCLC
  • Discuss how the MDT can support patient care by identifying potential barriers to MDT working practices and by actively incorporating new research findings into NSCLC management
Lung Cancer
Watch Time: 56 mins
touchCONGRESS
Progress in the management of EGFR-mutant NSCLC in 2020: Where are we now?
Dr Roy S Herbst, Prof. David Planchard, Dr Shun Lu

Watch expert review and interpretation of the latest findings for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC) in this webinar from the American Society of Clinical Oncology Virtual 2020 Conference (ASCO20 Virtual), 29–31 May 2020. Part 1: Watch internationally renowned expert Dr Roy Herbst review the key data from ASCO20 Virtual Part 2: Choose from leading experts who discuss what data finding mean for global and regional practice

Learning objectives
Learning Objectives
  • Recall efficacy and safety data for EGFR-TKIs for patients with EGFR-mutant NSCLC, including those with early-stage disease
  • Describe how molecular testing can help guide appropriate therapeutic approaches for patients with EGFR-mutant NSCLC
  • Discuss how the treatment pathway for the use of targeted therapies in the management of EGFR-mutant NSCLC is evolving now and in the future

Other Curriculum Activities

Learn more with a series of activities which are linked and developed as a curriculum

Multiple Myeloma
touchCURRICULUM
Multiple Myeloma

Learn more about the role of BCMA-targeting agents in the treatment of multiple myeloma.

Including:

touchPANEL DISCUSSION

Integrating BCMA-targeting agents into the treatment pathway for relapsed/refractory multiple myeloma

touchCONGRESS

Advances in the role of BCMA-targeting agents in multiple myeloma: An update from the EHA Congress 2021

touchEXPERT OPINIONS

Managing adverse events associated with BCMA-targeting agents in multiple myeloma: The role of the multidisciplinary team

Multiple Myeloma
Curriculum Inclusions:
  • Describe the potential of BCMA-targeting agents to improve outcomes for patients with multiple myeloma
  • Discuss the use of BCMA-targeting agents for relapsed/refractory multiple myeloma in clinical practice
  • Summarize the key adverse events associated with BCMA-targeting agents and how they can be managed
Ovarian Cancer
touchCURRICULUM
Ovarian Cancer

Watch interviews and latest expert perspectives on clinical best practice for optimzing the management of advanced ovarian cancer with PARP inhibitors as first-line maintenance therapy.

Including:

touchCONGRESS

PARP inhibitors as first-line maintenance therapy in ovarian cancer: Using data from SGO 2022 to inform clinical best practice

touchIN CONVERSATION

Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancer: Improving patient identification and treatment selection

touchCONGRESS

PARP inhibitors as first-line maintenance therapy in ovarian cancer: How can data from ESGO 2022 guide clinical practice?

Ovarian Cancer
Curriculum Inclusions:
  • Discuss the rationale for using PARP inhibitors in the first-line maintenance treatment of advanced ovarian cancer
  • Identify patients who may benefit from a PARP inhibitor as first-line maintenance therapy and key factors informing selection of the most appropriate PARP inhibitor for each patient
  • Describe the latest efficacy and safety data for PARP inhibitors in the first-line maintenance setting for advanced ovarian cancer and how insights from clinical trials and the real world may impact current clinical practice
IME
CME activities are developed by touchIME for touchONCOLOGY.

Our education resources are developed in collaboration with our well established peer-reviewed medical journals, our Editorial Board members and partnerships with major medical societies, with a clear commitment to high-quality independent education.

In Partnership with...
Useful Links:
About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
Connect With Us:

Other websites from Touch Medical Media:

touchONCOLOGY
touchOPHTHALMOLOGY
touchENDOCRINOLOGY
touchNEUROLOGY
touchCARDIO
touchRESPIRATORY
touchIMMUNOLOGY
touchINFECTIOUS DISEASES
touchHAEMATOLOGY
touchDERMATOLOGY

Copyright® 2025 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup